Adverse Drug Reaction Assessment

Adverse drug reaction assessment is the process of recognising a suspected adverse drug reaction, judging how likely it is that a particular medicine caused it, and recording it so that the signal can contribute to pharmacovigilance. It combines clinical reasoning about timing, dechallenge and rechallenge, and alternative explanations with structured causality instruments and spontaneous reporting systems.

Definition

Adverse drug reaction assessment is the structured appraisal of whether a noxious, unintended response to a medicine given at normal doses was caused by that medicine, using clinical features, temporal relationships, and causality instruments, and the documentation of that judgement for surveillance.

Scope

The topic covers the definition and classification of adverse drug reactions, the logic of causality assessment, the structured tools used to grade it, and the reporting systems that aggregate suspected reactions. It is framed as a reference and methodological topic; it describes how reactions are appraised and reported rather than directing the care of an individual patient.

Core questions

• What makes a response to a medicine a reportable adverse drug reaction rather than coincidence?
• How is the probability that a given drug caused a reaction estimated and graded?
• What roles do dechallenge, rechallenge, and timing play in causality judgement?
• How do spontaneous reports become signals at the population level?

Key concepts

• Type A versus type B reactions
• Causality assessment
• Dechallenge and rechallenge
• Naranjo probability scale
• Spontaneous reporting
• Signal detection
• Seriousness and severity

Mechanisms

Assessment begins by establishing that a reaction is plausibly drug-related: the temporal relationship between exposure and event, whether the reaction abated on stopping the drug (dechallenge) or recurred on re-exposure (rechallenge), the existence of alternative causes, and consistency with the drug's known pharmacology. Edwards and Aronson (2000) frame the underlying dose-dependent type A and idiosyncratic type B distinction that guides expectation. Structured instruments translate these features into a probability category — the Naranjo scale (1981) being the most widely used algorithm, scoring weighted questions into definite, probable, possible, or doubtful categories. Confirmed reactions feed reporting systems that aggregate cases to detect population-level signals (WHO 2002).

Clinical relevance

Consistent assessment and reporting of suspected reactions underpins pharmacovigilance and the post-marketing safety knowledge clinicians rely on, and adverse reactions are a frequent reason for hospital admission (Pirmohamed 2004). The topic is presented descriptively to explain how causality is judged and how reports become signals; it is educational and not a protocol for managing any individual reaction.

Epidemiology

Adverse drug reactions account for a substantial share of hospital presentations, with Pirmohamed and colleagues (2004) attributing roughly one in sixteen admissions in their cohort to ADRs, most judged at least possibly avoidable. Spontaneous reporting systems are known to under-capture reactions, so assessed and reported cases represent a fraction of true incidence; this under-reporting shapes how signals are interpreted (WHO 2002).

History

Structured causality assessment emerged in the 1970s and early 1980s as pharmacovigilance matured; Naranjo and colleagues published their probability algorithm in 1981, giving the field a reproducible scoring method. Definitional and classificatory work by Edwards and Aronson (2000) consolidated the conceptual basis, while the WHO Programme for International Drug Monitoring built the international reporting infrastructure that turns individual assessments into population signals.

Debates

How reliable are causality assessment instruments?

Structured scales such as the Naranjo algorithm improve reproducibility over unstructured judgement, but inter-rater agreement is imperfect and no instrument establishes causation with certainty, so assessment remains a probabilistic judgement.

Key figures

• Jeffrey Aronson
• Ralph Edwards
• Claudio Naranjo

Seminal works

• edwards-aronson-2000
• naranjo-1981

Frequently asked questions

What is the Naranjo scale used for?

It is a structured questionnaire that scores features such as timing, dechallenge, rechallenge, and alternative causes to categorise the probability that a medicine caused a suspected adverse reaction.

Why are spontaneous reports of adverse reactions still valuable despite under-reporting?

Even an incomplete stream of reports can reveal rare or delayed reactions not seen in pre-marketing trials, generating signals that prompt further investigation.